Investigation of the Effect of Age and Injury Severity on Short-term Intra-hospital Outcomes After Surgical Stabilized Rib Fractures
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Michael D Huelskamp, Dr. med.
- Phone Number: 0049 (0)251 83 51786
- Email: Michael.Huelskamp@ukmuenster.de
Study Contact Backup
- Name: Helena Duesing, Dr. med.
- Email: Helena.Duesing@ukmuenster.de
Study Locations
-
-
North Rhine-Westphalia
-
Münster, North Rhine-Westphalia, Germany, 48149
- Department for trauma, hand and reconstructive surgery, University hospital Muenster
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients of the University Hospital Muenster
- Coded serial rib fractures (ICD S22.4 and S22.5)
- Treatment for the rib fractures between 2019 and 2023
Exclusion Criteria:
- pathological rib fractures (due to suspected malignancy)
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Operative
Patients receiving surgical stabilisation of rib fractures (SSRF) by any operative technique
|
Surgical stabilisation of rib fractures using any fixation technique (including but not limited to plate fixation, intramedullary fixation, wire fixation) via any operative approach (including but not limited to open external approach, minimally invasive approach, thoracoscopic approach, thoracotomy approach).
Any supportive or specific treatment of rib fractures excluding surgical stabilisation of rib fractures.
This includes, but is not limited to analgesia, physiotherapy, non-invasive ventilation, mechanical ventilation, oxygen-supplementation
|
|
Non-operative
Patients not receiving surgical stabilisation of rib fractures (SSRF)
|
Any supportive or specific treatment of rib fractures excluding surgical stabilisation of rib fractures.
This includes, but is not limited to analgesia, physiotherapy, non-invasive ventilation, mechanical ventilation, oxygen-supplementation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
In hospital-mortality
Time Frame: From injury up to initial hospital discharge or death, whichever came first, assessed up to 2 month.
|
Mortality rate from injury to initial hospital discharge, binary
|
From injury up to initial hospital discharge or death, whichever came first, assessed up to 2 month.
|
|
Intensive care unit length of stay
Time Frame: From injury up to initial hospital discharge or death, whichever came first, assessed up to 2 month.
|
The duration in days a patient spent in the intensive care unit from the time of hospital admission to the time of initial hospital discharge.
|
From injury up to initial hospital discharge or death, whichever came first, assessed up to 2 month.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intubation rate
Time Frame: From injury up to initial hospital discharge or death, whichever came first, assessed up to 2 month.
|
Proportion of patients intubated at any time
|
From injury up to initial hospital discharge or death, whichever came first, assessed up to 2 month.
|
|
Multi-organ failure
Time Frame: From injury up to initial hospital discharge or death, whichever came first, assessed up to 2 month.
|
Rate of Multi-organ failure
|
From injury up to initial hospital discharge or death, whichever came first, assessed up to 2 month.
|
|
Single organ failure
Time Frame: From injury up to initial hospital discharge or death, whichever came first, assessed up to 2 month.
|
Rate of single organ failure
|
From injury up to initial hospital discharge or death, whichever came first, assessed up to 2 month.
|
|
Sepsis
Time Frame: From injury up to initial hospital discharge or death, whichever came first, assessed up to 2 month.
|
Rate of Sepsis
|
From injury up to initial hospital discharge or death, whichever came first, assessed up to 2 month.
|
|
Lung-failure
Time Frame: From injury up to initial hospital discharge or death, whichever came first, assessed up to 2 month.
|
Rate of Lung-failure
|
From injury up to initial hospital discharge or death, whichever came first, assessed up to 2 month.
|
|
Clinical outcome
Time Frame: At the time point of initial hospital discharge or at death, whichever came first, assessed up to 2 month.
|
Clinical outcome according to the Glasgow outcome scale (GOS)
|
At the time point of initial hospital discharge or at death, whichever came first, assessed up to 2 month.
|
|
Duration of hospital stay
Time Frame: From injury up to initial hospital discharge or death, whichever came first, assessed up to 2 month.
|
Duration of hospital stay in days from injury to initial discharge
|
From injury up to initial hospital discharge or death, whichever came first, assessed up to 2 month.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Steffen Rosslenbroich, PD Dr. med., Department for trauma, hand and reconstructive surgery, University hospital Muenster
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- UKM_UCH_2024_002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.